Filing Flows › ARS Pharmaceuticals (SPRY) › R&D spending
ARS Pharmaceuticals (SPRY) R&D spending by quarter
ARS Pharmaceuticals' R&D spending was $18.3M in Q3 2026 (third quarter 2026), +289% from Q2 2026. Over the last 7 quarters it ranged from $2.8M (Q3 2025) to $18.3M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $18.3M | +289% | +564% |
| Q2 2026 | $4.7M | +8% | +16% |
| Q1 2026 | $4.3M | +26% | +47% |
| Q4 2025 | $3.4M | +25% | — |
| Q3 2025 | $2.8M | -32% | — |
| Q2 2025 | $4.0M | +37% | — |
| Q1 2025 | $3.0M | — | — |
Q3 2026 at a glance
ARS Pharmaceuticals, Q3 2026: revenue $37.7M (+16% year over year), operating margin -90.6%, net loss $35.6M, operating cash flow −$33.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is ARS Pharmaceuticals' R&D spending?
ARS Pharmaceuticals' R&D spending was $18.3M in Q3 2026 (third quarter 2026), +289% from Q2 2026.
How has ARS Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $2.8M (Q3 2025) to $18.3M (Q3 2026).